Login to Your Account



Qnexa's Fate to Serve as a Guide for Other Obesity Drugs

By Mari Serebrov
Washington Editor

Thursday, July 12, 2012
If the FDA greenlights Vivus Inc.'s Qnexa next week, it won't just be giving the market go-ahead to a second obesity drug. It will be opening up a new lane for weight-loss drugs containing an anticonvulsant.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription